I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Salubris (002294.SZ) announced that it recently received the acceptance notice issued by the National Medical Products Administration. The clinical trial application for the new indication of the independently developed innovative small molecule drug SAL0140 tablets (project code: SAL0140) has been accepted.
SAL0140 is a mineralocorticoid synthase inhibitor with independent intellectual property rights, intended to develop indications including uncontrolled hypertension (including resistant hypertension), chronic kidney disease (CKD), and primary aldosteronism. Currently, SAL0140 (uncontrolled hypertension) is about to enter Phase II clinical trials.
It is reported that aldosterone is the most important mineralocorticoid hormone in the human body, which can maintain the balance of body fluids and electrolytes, and directly participate in the target organ damage of various cardiovascular and kidney diseases. Primary aldosteronism is characterized by excessive autonomous secretion of aldosterone from the adrenal cortex, leading to sodium retention, potassium excretion, increased blood volume, and suppression of the renin-angiotensin system. The main clinical features are hypertension, cardiovascular damage, sodium retention, and often hypokalemia, making it one of the common causes of secondary hypertension. Primary aldosteronism accounts for 5% to 15% of the hypertensive population; among newly diagnosed hypertensive patients, the prevalence of primary aldosteronism exceeds 4%, and the prevalence increases with higher blood pressure levels, accounting for about 20% in resistant hypertension patients. Compared with patients with primary hypertension, those with primary aldosteronism have more severe target organ damage and a higher risk of cardiovascular disease. Mineralocorticoid synthase inhibitors are expected to lower the aldosterone levels in patients with primary aldosteronism by directly inhibiting aldosterone synthesis, thereby reducing blood pressure and organ damage, showing certain development potential.
If SAL0140 can be successfully developed and approved for marketing, it is expected to provide targeted new medication options for patients in more segmented fields, meet unmet clinical needs, and further enrich the company's innovative product pipeline in the chronic disease field